Telemonitoring type 1 diabetes patients during the COVID-19 pandemic in Brazil: was it useful?

Alessandra Saldanha de Mattos Matheus¹
Carolina Alves Cabizuca¹
Lucianne Righetti Monteiro Tannus¹
Aline Camin Passos²
Amábile Cristyne Schmidt²
Ana Tarasiuk de Gouveia²
Bruno Moraes de Albuquerque Pessoa²
Felipe Cerqueira Matheus²
Gabriela Ye-Huey Yang²
Josimara Araujo da Silva Divino²
Juliana Alfonso Mathiles²
Juliana Leite Teixeira²
Luiza de Souza Barroso²
Max Benicio da Fonseca de Brito²
Paula Melichar Suassuna²
Roberta Arnoldi Cobas²

ABSTRACT

Objectives: To evaluate the performance of telemonitoring in detecting clinical and psychological needs and adherence to the protective measures imposed by the COVID-19 pandemic in addition to providing remote assistance for patients with type 1 diabetes (T1D) in a public university center in Brazil.

Subjects and methods: Telemonitoring protocol included phone calls and e-mails. Patients were asked to rate COVID-19-like symptoms, psychological symptoms, epidemiological issues, and adherence to diabetes management (insulin, exercise, and diet) using a 0-to-10 scale. An e-mail address and phone number were offered for further contact if needed. Clinical, demographic, and laboratorial data from the consultations before the pandemic were collected from medical records.

Results: Among 321 patients with a previously scheduled consultation over the first 15 weeks of social distancing, 237 (73.8%) could be successfully contacted. Of these, 207 (87.3%) were exclusively evaluated by telemonitoring (190 only by phone or text message and 17 who were also reached by email), and 30 (12.7%) patients attended the consultation for medical reasons detected during the telephone screening. Overall, 44 (18.5%) patients reported COVID-19-like symptoms. One (2.3%) patient was hospitalized and subsequently died. Psychological symptoms were reported by 137 (60.4%) patients and 30 (12.7%) required remote psychological assistance. Appropriate social distancing was performed by 203 (87.9%) patients, and 221 (97.8%) referred use of masks.

Conclusions: Telemonitoring T1D patients during the pandemic helped reduce the need for in-person consultations, detect clinical and psychological needs, and offer support to patients in addition to monitoring suspected COVID-19 cases and the adherence to protective measures.

Keywords
Type 1 diabetes; COVID-19; telemonitoring
INTRODUCTION

Diabetes and poor glycemic control are risk factors for adverse outcomes of COVID-19, such as severe acute respiratory syndrome (SARS) and death (1,2). In a multicenter study including type 1 diabetes (T1D) patients with confirmed or suspected COVID-19, 17.5% required hospital admission, and 22.2% required intensive care, and one-third experienced diabetic ketoacidosis. These results reinforce the importance of closely monitoring patients with T1D during the COVID-19 pandemic (3).

The International Diabetes Federation (4) and the Brazilian Diabetes Society (5) published specific recommendations for this period, such as self-monitoring blood glucose to avoid hyper- or hypoglycemia, guidance about COVID-19 symptoms, awareness of immediate medical evaluation, and assurance of a suitable stock of medications and supplies. However, the multidisciplinary therapeutic approach usually recommended for diabetes care was no longer feasible during the COVID-19 pandemic due to the determination of social distancing. Therefore, the replacement of the usual in-person consultations with remote monitoring became urgently needed, leading to changes in many regulatory rules to telehealth (6) and unprecedented interactions among health care providers and patients (7).

In accordance with the demands imposed by the pandemic, the medical team at the Rio de Janeiro State University’s Diabetes Unit instituted a telemonitoring protocol to manage patients with T1D, thereby minimizing their exposure risk.

The aim of this study was to evaluate the performance of telemonitoring in detecting clinical and psychological needs and adherence to the protective measures imposed by the COVID-19 pandemic in addition to providing remote assistance for patients with T1D in a public university center in Brazil.

SUBJECTS AND METHODS

This observational study was conducted at the Diabetes Unit of Rio de Janeiro State University during the COVID-19 pandemic. The study was approved by the center’s local ethics committee, and Plataforma Brasil’s Certificado de Apresentação para Apreciação Ética (CAEE) number was 31780320.8.0000.5259.

Outpatients with T1D (defined by American Diabetes Association criteria) receiving follow-up treatment at our unit who had an appointment scheduled for the pandemic period (March to June 2020) were eligible for telemonitoring. We excluded those whom we did not successfully contact from further analysis because telemonitoring was not feasible.

Clinical, demographic, and laboratorial data recorded in the last consultation before the pandemic were collected from medical records: age, duration of diabetes, body mass index (BMI), diagnosis of hypertension, diabetic retinopathy, diabetic neuropathy, and glomerular filtration rate (estimated by the Chronic Kidney Disease Epidemiology Collaboration creatinine equation in adults (8) or the Schwartz equation (9) for children and adolescents < 18 years). Patients were classified as children (younger than 19 years old), adults (between 19 and 59 years old), and older adults (60 years old or older). Renal dysfunction was considered a glomerular filtration rate less than 60 ml/min/1.73 m². Patients were considered overweight or obese if BMI ≥ 25 or ≥ 30 kg/m² in adults, and ≥ 85th and ≥ 95th percentile in subjects < 18 years old, respectively.

The information assessed through telephone calls was as follows:

1. Clinical data: presence of symptoms suggestive of COVID-19 (fever, cough, headache, anosmia, loss of taste, myalgia, and shortness of breath, as well as fatigue and gastrointestinal symptoms); availability of tests for diagnostic confirmation; and hospitalization or death.
2. Epidemiological data: close contact with individuals suspected or confirmed to have COVID-19, adherence to social distancing and mask recommendations, and influenza vaccination. Social distancing was classified as total if the patients remained at home all the time, partial if the patients left the house only for essential activities of short duration, and absent if they left home for work or nonessential activities. Appropriate use of masks was considered when the recommendation to use them outside home was respected.
3. Difficulties in acquisition of supplies for diabetes treatment.
4. Adherence to diabetes management: taking medication (0 to 10 scale), diet (0 to 10 scale), and self-reported frequency of physical exercise.
5. Psychological effects of the COVID-19 pandemic: presence of symptoms such as anxiety, fear, and insomnia, as well as the need for support by a mental health professional.
Statistical analysis

The statistical analysis was performed using SPSS version 25.0.

Nonparametric data are presented as median values (interquartile range). Mann-Whitney test was used for comparison between variables with nonparametric distribution and chi-square test was used to compare frequencies. A two-sided P value < 0.05 was considered statistically significant.

RESULTS

From 321 T1D patients with previously scheduled appointments for the period of COVID-19 pandemic, 237 (73.8%) could be successfully contacted by phone. For 84 (26.2%) patients, telemonitoring was not possible because of wrong phone numbers in the register or the patients did not answer the call despite multiple attempts. Of the 237 patients contacted by phone, 207 (87.3%) were exclusively evaluated by telemonitoring (190 only by phone or text message and 17 who were also reached also by email), and 30 (12.7%) patients attended consultations for medical reasons detected during the telephone screening (Figure 1).

No differences were observed in clinical and demographic data between patients successfully and unsuccessfully contacted for telemonitoring (data not shown).

Among successfully contacted patients, the majority were adults (63.7%) with a diabetes duration of 12 [5.5-22] years and A1c of 8.7% [7.7-10]. Clinical and anthropometric characteristics are presented in Table 1.

Overall, 44 (18.5%) patients described COVID-19-like symptoms. Of those, 25% were pediatric patients, 72.7% were adults, and 2.3% elderly people. One patient was hospitalized and died (2.3%) during this period (Table 1). It is important to mention that she had T1D for 14 years, cardiac autonomic, peripheral neuropathy and retinopathy with a poor glycemic control (last A1c was 12.3%), and whose BMI was 18 kg/m².

Considering the type of COVID-19-like symptom, fever (40.9%), myalgia (36.4%), headache (34.1%), and cough (31.8%) were the most prevalent. Other symptoms included loss of taste (27.3%), loss of smell (20.5%), shortness of breath (20.5%), and others (27.3%). Whether patients presented symptoms or not, no difference in sex, age, duration of diabetes, A1c levels, or presence of chronic complications was observed between them. Epidemiological data and adherence to preventive measures were also not different (Table 1).

Thirty (12.7%) patients required psychological attention performed through telemedicine, mostly in the symptomatic group (11 [25%] vs. 19 [9.8%]; P = 0.006; Table 1) The most prevalent psychological symptoms attributable to the COVID-19 pandemic were fear, insomnia, and anxiety, affecting 39.4%, 29.6%, and 46.3% of patients, respectively. The presence of psychological symptoms was not associated with gender, duration of diabetes, A1c levels, BMI, or adherence to insulin treatment or diet. Patients with psychological symptoms were older (30 [18-44] vs. 21.5 [15-38.5] years old, P = 0.044) and practiced physical exercise less frequently (29 [21.2%] vs. 33 [37.1%], P = 0.009). In addition, the adherence to diet was greater in patients who also adhered to physical activity (7.75 [6-9] vs. 7 [5-8], P = 0.012).

A higher proportion of pediatric and older patients respected social distancing (95.9% and 91.6%, respectively) compared to adults (83.5%, P = 0.001). Of those not completely social distancing, the majority in all age groups said they used masks outside. The adherence to influenza vaccination was higher in the older group (83.3%) compared to the adult (58.6%) and pediatric groups (46.5%, P = 0.036; Table 2).

The effect of the pandemic on diabetes treatment stratified by age groups is presented in Table 2. Overall, 17.3% of the patients referred to difficulties acquiring medical supplies. The self-reported scores for adherence to diet and exercise frequency were similar among age groups. The self-reported score for insulin treatment adherence was different among age groups (10 [9-10] in pediatric cases vs 9 [8-10] in adult and 10 [8-10] in older person’s cases, P = 0.004).
### Table 1. Clinical and epidemiological data from the whole population and comparison between symptomatic and asymptomatic patients

|                          | Total      | COVID-19-like symptomatics | Asymptomatics | P value |
|--------------------------|------------|----------------------------|---------------|---------|
| N                        | 237        | 44                         | 193           |         |
| Gender (Female)           | 129 (54.4%)| 28 (63.6%)                 | 101 (52.3%)   | 0.174   |
| Age (years)               | 27 [16-43] | 33 [18.5-43]               | 26 [16-43]    | 0.532   |
| Pediatric                 | 74 (31.2%) | 11 (25)                    | 63 (32.6%)    | 0.334   |
| Adults                    | 151 (63.7%)| 32 (72.7)                  | 119 (61.7%)   |         |
| Elderly                   | 12 (5.1%)  | 1 (2.3)                    | 11 (5.7)      |         |
| Duration of diabetes (years) | 12 [5.5-22] | 16 [7.5-23.5]              | 12 [5-22]     | 0.255   |
| HbA1c (%)                 | 8.7 [7.7-10] | 8.6 [7.7-9.5]             | 8.7 [7.6-10.2] | 0.637   |
| Renal dysfunction         | 16 (9.2%)  | 1 (3.2)                    | 15 (10.6)     | 0.201   |
| Retinopathy               | 70 (40.5%) | 12 (40)                    | 58 (40.6)     | 0.955   |
| Neuropathy                | 30 (18.3%) | 8 (25)                     | 22 (16.7)     | 0.274   |
| Body mass index           | 23.4 [19.7-27.1] | 24.5 [21.2-28.6]       | 23.3 [19.7-26.9] | 0.428   |
| Eutrophic                 | 135 (57.2%)| 23 (52.3)                  | 112 (58.3)    | 0.762   |
| Overweight                | 68 (28.8%) | 14 (31.8)                  | 54 (28.1)     |         |
| Obesity                   | 33 (14%)   | 7 (15.9)                   | 26 (13.5)     |         |
| Hypertension              | 53 (22.8%) | 10 (22.7)                  | 43 (22.9)     | 0.984   |
| Frequency of symptoms     |            |                            |               |         |
| Fever                     | 18 (40.9%) |                            |               |         |
| Myalgia                   | 16 (36.4%) |                            |               |         |
| Headache                  | 15 (34.1%) |                            |               |         |
| Cough                     | 14 (31.8%) |                            |               |         |
| Dysgeusia                 | 12 (27.3%) |                            |               |         |
| Anosmia                   | 9 (20.5%)  |                            |               |         |
| Shortness of breath       | 9 (20.5%)  |                            |               |         |
| Others                    | 12 (27.3%) |                            |               |         |
| Hospitalization           | 1 (2.3%)   |                            |               |         |
| Death                     | 1 (2.3%)   |                            |               |         |
| Practice of exercise      | 62 (27.4%) | 10 (23.3)                  | 52 (28.4)     | 0.495   |
| Adherence to diet         | 7 [5.8-8]  | 7 [6-8]                    | 7 [5-8]       | 0.616   |
| Adherence to treatment    | 137 (60.4%)| 9 [8-10]                   | 10 [8-10]     | 0.174   |
| Psychological symptoms    | 137 (60.4%)| 28 [65.1]                  | 109 [53.2]    | 0.478   |
| Psychological consultation | 30 (12.7%) | 11 (25)                    | 19 (9.8)      | 0.006   |
| In-person consultation    | 30 (12.7%) | 4 (9.1)                    | 26 (13.5)     | 0.430   |
| Telemonitoring            | 207 (87.3%)| 40 (80.9)                  | 167 (86.5)    | 0.43066 |
| Influenza Vaccine         | 128 (56.1%)| 23 (53.5)                  | 105 (56.8)    | 0.697   |
| Contact with confirmed or suspected COVID-19 | 37 (15.8%) | 16 (38.1)                  | 21 (10.9)     | 0.000   |
| Social distancing         |            |                            |               |         |
| None                      | 28 (12.1%) | 6 (14)                     | 22 (11.7)     | 0.431   |
| Total                     | 136 (58.9%)| 28 (65.1)                  | 108 (57.4)    |         |
| Partial                   | 67 (29%)   | 9 (20.9)                   | 58 (30.9)     |         |
| Use of masks              | 221 (97.8%)| 42 (97.7)                  | 179 (97.8)    | 0.955   |

Data presented as n (%) or median [interquartile range]. Missing data: 8 patients; 8 patients; 17 patients; 1 patient; 5 patients; 11 patients; 11 patients; 13 patients; 10 patients; 9 patients; 3 patients; 6 patients; 11 patients. Data from chronic complications were obtained only for patients with criteria for annual screening.
Table 2. Clinical and epidemiological data from the whole population and stratification by age groups

|                                                | Pediatric population (n = 74) | Adults (n = 151) | Elderly (n = 12) | P value |
|------------------------------------------------|-----------------------------|-----------------|-----------------|---------|
| Close contact with suspected or confirmed case | 8 (11.1)                    | 28 (18.7)       | 1 (8.3)         | 0.270   |
| Social distancing                               |                             |                 |                 |         |
| None                                           | 3 (4.1)                     | 24 (16.4)       | 1 (8.3)         |         |
| Total                                          | 61 (83.6)                   | 71 (48.6)       | 4 (33.3)        |         |
| Partial                                        | 9 (12.3)                    | 51 (34.9)       | 7 (58.3)        | 0.001   |
| Use of masks, yes                              | 69 (98.6)                   | 140 (97.2)      | 12 (100)        | 0.711   |
| Influenza vaccination, yes                      | 33 (46.5)                   | 85 (58.6)       | 10 (83.3)       | 0.036   |
| Adherence to diet                              | 7 [5-9]                     | 7 [6-8]         | 6 [5-8]         | 0.699   |
| Adherence to insulin treatment, yes            | 10 [9-10]                   | 9 [8-10]        | 10 [8-10]       | 0.004   |
| Physical exercise, yes                         | 17 (23.9)                   | 43 (29.9)       | 2 (18.2)        | 0.513   |
| Problems in supplies acquisition, yes          | 9 (12.9)                    | 27 (18.8)       | 3 (27.3)        | 0.379   |
| Psychological symptoms                         | 35 (48.6)                   | 95 (66)         | 7 (63.6)        | 0.047   |
| Psychologic telemonitoring required            | 7 (9.5)                     | 21 (13.9)       | 2 (16.9)        | 0.585   |

Missing data: 3 patients; 6 patients; 9 patients; 11 patients; 13 patients; 11 patients; 12 patients; 10 patients.

DISCUSSION

During the COVID-19 pandemic, telemonitoring was expected to play an important role in assisting patients with chronic diseases to avoid their exposure to SARS-CoV-2 infection. However, the success of this strategy in monitoring T1D patients in the public health system in Brazil was unknown, as was the effect of the pandemic on patients’ physical and mental health. To fill this gap, our study showed that telemonitoring reached 74% of T1D patients followed-up at our diabetes unit during the COVID-19 pandemic, and it allowed us to select urgent cases requiring in-person consultation and provide treatment guidance and psychological support to reinforce protective measures. Brazil’s health care system is traditionally structured on the model of face-to-face interactions between patients and clinicians, and this paradigm shift, especially under an urgent circumstance, was a major challenge.

To ratify our expectations, a 2015 Cochrane systematic review has already shown that telemedicine can result in improved blood glucose control in patients with diabetes (10). Similarly, children with asthma seen by telemedicine or in-person visits can achieve comparable degrees of asthma control (11). A recent Brazilian publication proposed that telehealth offers capabilities for remote screening, care, and treatment, and it assists monitoring, surveillance, detection, prevention, and mitigation of the effects on health care indirectly related to COVID-19 (12).

The prevalence of symptoms suggestive of COVID-19 in our population was 18.8%. Although the association with worse outcomes in patients with diabetes is well established (2), the susceptibility to SARS-CoV-2 infection does not appear to be increased in these patients (13,14). Thus, it is expected that infection rate among people with diabetes does not differ from the general population. Although none of the suspected COVID-19 cases could be confirmed due to lack of testing, almost all patients presented mild to moderate symptoms and one needed hospitalization and later died in this period. The absence of diagnostic confirmation can be explained by the low access to diagnostic tests because the public health strategy in Brazil was to test only severe cases of the disease. In fact, other respiratory viruses can be responsible for infections during this period (15) and data from the Brazilian Ministry of Health showed that COVID-19 was responsible for 53% of cases of hospitalization for SARS and 47% were due to other causes (16).

The T1D patients’ adherence to social distancing was high: 95.9%, 83.6%, and 91.7% of pediatric, adult, and older patients, respectively. In addition, almost all patients who did not perform distancing or did so partially adhered to the use of masks. According to data obtained by the technology company In Loco using a methodology for monitoring cellular signals, our findings were higher than the 40.1% social distancing rate observed in the State of Rio de Janeiro on June 23,
2020, and the 37.8% rate in Brazil on the same day. The maximum distancing rate recorded for the population in Rio de Janeiro since the beginning of lockdown was 64.1% on March 22, 2020 (17).

The COVID-19 pandemic may be associated with the onset or worsening of people’s psychological disorders (18). The reduced contact with friends, familial support, and social network imposed by social distancing can trigger anxiety, fear, and sleep disorders. Particularly in patients with chronic diseases, including diabetes, these psychological symptoms may worsen due to the fear of clinical decompensation and adverse outcomes associated with COVID-19. The majority of our patients reported symptoms such as feeling anxious, feeling fearful, or difficulty sleeping, regardless of the presence of COVID-19-like symptoms. However, a greater number of COVID-19-like symptomatic patients asked for psychological support. According to a recent study based on telemedicine, 88.4% of older type 2 diabetes patients felt anxiety related to the current pandemic (19).

We observed a low adherence to physical exercise, which could be explained by the difficulty of exercising at home. However, studies prior to the COVID-19 pandemic have already shown that physical activity was performed by only 34% of patients with diabetes and the main reasons for inactivity included the perception of difficulty in exercising, feeling tired, and lack of time or local facilities (20,21). In addition, the score given to diet was lower than that attributed to the use of insulin in our study. Although dietary recommendations are important for optimal self-management in T1D patients, data show that this is one of the most difficult treatment pillars to follow (21).

Our study has some limitations. First, we were not able to contact all patients scheduled for consultations during the pandemic, which could have led to underestimation of the number of symptomatic patients and the number of hospitalizations or deaths. Furthermore, no symptomatic patient had a confirmatory test for COVID-19, so we cannot assure the etiology of flu-like syndrome.

To overcome the barriers to providing telemonitoring that we encountered, periodic updates of personal information in medical records must be performed. Moreover, considering that a multidisciplinary approach is essential for good metabolic control, supplementary to medical and psychological support, we propose that strategies be developed to provide nutritional guidance and physical exercise programs that can be easily performed at home.

In summary, telemonitoring T1D patients from our public diabetes center during the COVID-19 pandemic was useful to reduce the need for in-person consultations and to detect clinical and psychological needs while providing remote assistance for patients. In addition, phone contact allowed us to reinforce the recommended protective measures to minimize risk of SARS-CoV-2 exposure.

Acknowledgments: none declared.

Funding: none declared.

Disclosure: no potential conflict of interest relevant to this article was reported.

REFERENCES

1. Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging. 2020;12(7):6049-57.
2. The OpenSAFELY Collaborative: OpenSAFELY factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. [Preprint]. 2020 [cited 2020 June 20]; [22p]. Available from: https://www.medrxiv.org/content/10.1101/2020.05.06.20092999v1.
3. Ebekozien OA, Noar N, Gallagher MP, Alonso GT. Type 1 Diabetes and COVID-19: Preliminary findings from a Multicenter Surveillance Study in the U.S. Diabetes Care. 2020;43(8):e83-5.
4. International Diabetes Federation [Internet] [cited 2020 Apr 23]. COVID-19 and Diabetes. Available from: https://www.idf.org/aboutdiabetes/what-is-diabetes/covid-19-and-diabetes.html.
5. Sociedade Brasileira de Diabetes [Internet] [cited 2020 Apr 24]. Notas de esclarecimentos da Sociedade Brasileira de Diabetes sobre o Coronavirus – COVID-19. Available from: https://www.diabetes.org.br/covid-19/notas-de-esclarecimentos-da-sociedade-brasileira-de-diabetes-sobre-o-coronavirus-covid-19/.
6. Teles M, Sacchetta T, Matsumoto Y. COVID-19 Pandemic triggers telemedicine regulation and intensifies Diabetes Management Technology adoption in Brazil. J Diabetes Sci Technol. 2020;14(4):797-8.
7. Danne T, Lindberg C. COVID-19, type 1 diabetes, and technology: why paediatric patients are leading the way. Lancet Diabetes. Endocrinol. 2020;8(6):465-7.
8. KDIGO CKD Work Group Kidney Disease: Improving Global Outcomes. Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1-150.
9. Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20(3):629-37.
10. Flodgren G, Rachas A, Farmer AJ, Inzitari M, Shepperd S. Interactive telemedicine: effects on professional practice and health care outcomes. Cochrane Database Syst Rev. 2015;(9):CD002098.
11. Parenty JM, Waller M, De Lurgio S, Dinakar C. Telemedicine is as effective as in-person visits for patients with asthma. Ann Allergy Asthma Immunol. 2016;117:241-5.
12. Caetano R, Silva AB, Guedes ACCM, de Paiva CCN, Ribeiro GR, Santos DL, et al. Challenges and opportunities for telehealth during the COVID-19 pandemic: ideas on spaces and initiatives in the Brazilian context. Cad Saude Publica. 2020;36(5):e00088920.

13. Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109(5):531-8.

14. Fadini GP, Morieri ML, Longato E, Avogaro A. Prevalence and impact of diabetes among people infected with SARS-CoV-2. J Endocrinol Invest. 2020;43(6):867-9.

15. Sociedade Brasileira de Imunização [Internet] [cited 2020 June 23]. Available from: Notas Técnicas – Campanha Influenza. Available from: https://sbim.org.br/images/files/notas-tecnicas/informe-tecnico-ms-campanha-influenza-2020-final.pdf.

16. Ministério da Saude [Internet] [cited 2020 June 24]. Available from: https://susanalitico.saude.gov.br/#/dashboard/.

17. In Loco [Internet] [cited 2020 June 24]. Available from: https://public.tableau.com/profile/inlocotableau#/vizhome/MKTScoredeisolamentosocial/VisoGeral.

18. Canadian Mental Health Association, BC Division [Internet]. [cited 2020 June 25]. COVID19 and anxiety. Available from: https://www.heretohelp.bc.ca/infosheet/covid-19-and-anxiety.

19. Fatyga E, Dziegielewska-Gęsiak S, Wierzęgoń A, Stoltyny D, Muc-Wierzęgoń M. The COVID-19 pandemic: the use of telemedicine in elderly patients with type 2 diabetes. Pol Arch Intern Med. 2020;130(5):452-4

20. Brazeau AS, Rabasa-Lhoret R, Strychar I, Mircescu H. Barriers to physical activity among patients with type 1 diabetes. Diabetes Care. 2008;31:2108-9.

21. Thomas N, Alder E, Leese G. Barriers to physical activity in patients with diabetes. Postgrad Med J. 2004;80(943):287-91.